newsfilter
← Latest News
Business Wire·

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

- Authorization includes oral solution and tablet formulation to support flexible dosing Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that Health Canada has authorized